Synthetic extracellular volume fraction without hematocrit sampling for hepatic applications

Narine Mesropyan1,2 · Patrick Kupczyk1,2 · Alexander Isaak1,2 · Christoph Endler1,2 · Anton Faron1,2 · Leona Dold3 · Alois M. Sprinkart1,2 · Claus C. Pieper1 · Daniel Kuetting1,2 · Ulrike Attenberger1 · Julian A. Luetkens1,2

Received: 3 January 2021 / Revised: 3 May 2021 / Accepted: 22 May 2021 / Published online: 10 June 2021
© The Author(s) 2021

Abstract
Purpose Calculation of extracellular volume fraction (ECV) currently receives increasing interest as a potential biomarker for non-invasive assessment of liver fibrosis. ECV calculation requires hematocrit (Hct) sampling, which might be difficult to obtain in a high-throughput radiology department. The aim of this study was to generate synthetic ECV for hepatic applications without the need for Hct sampling.

Methods In this prospective study participants underwent liver MRI. T1 mapping was performed before and after contrast administration. Blood Hct was obtained prior to MRI. We hypothesized that the relationship between Hct and longitudinal relaxation rate of blood \( R1_{\text{blood}} \) could be calibrated and used to generate the equation for synthetic Htc and ECV calculation. Conventional and synthetic ECV were calculated. Pearson correlation, linear regression and Bland–Altman method were used for statistical analysis.

Results 180 consecutive patients were divided into derivation (\( n = 90 \)) and validation (\( n = 90 \)) cohorts. In the derivation cohort, native \( R1_{\text{blood}} \) and Hct showed a linear relationship \( (\text{Hct}_{\text{MOLLI}} = 98.04 \times (1/R1_{\text{blood}}) - 33.17, R^2 = 0.75, P < 0.001) \), which was used to calculate synthetic ECV in the validation and whole study cohorts. Synthetic and conventional ECV showed significant correlations in the derivation, validation and in the whole study cohorts \( (r = 0.99, 0.97 \text{ and } 0.99, \text{ respectively, } P < 0.001, \text{ respectively}) \) with minimal bias according to the Bland–Altman analysis.

Conclusion Synthetic ECV seems to offer an alternative method for non-invasive quantification of the hepatic ECV. It may potentially overcome an important barrier to clinical implementation of ECV and thus, enable broader use of hepatic ECV in routine clinical practice.

Keywords Magnetic resonance imaging · Extracellular volume fraction · Liver fibrosis · Hematocrit

Abbreviations
MRI Magnetic resonance imaging
ECV Extracellular volume fraction
Htc Hematocrit

Introduction
Chronic liver disease is a global public health concern and accounts for approximately 2 million deaths per year worldwide [1]. Liver cirrhosis as a consequence of chronic liver disease is currently the 11th most common cause of death globally and within the top 20 causes of disability-adjusted life years and years of life lost [2]. The detection and staging of liver fibrosis is of great clinical importance for treatment decisions and prognosis estimation, therefore, reliable tools are necessary in these patients. Although considered the gold standard, liver biopsy has its clear drawbacks and, therefore, is no longer routinely performed for staging and monitoring of liver fibrosis. Consequently, non-invasive techniques such as transient elastography and magnetic resonance elastography (MR-elastography) are increasingly preferred in order to diagnose and grade liver fibrosis. Especially MR-elastography...
is considered one of the most accurate non-invasive technique for liver fibrosis assessment with accuracies varying from 89 to 95% depending on fibrosis stage and underlying liver disease [3, 4]. However, it can be associated with a high technical failure rate, i.e., in patients with massive ascites, obesity or iron deposition [5, 6].

In differentiating between normal and diseased liver parenchyma, the concept of evaluating the T1 relaxation times was first mentioned in the 1980s. Hepatic fibrosis increases the T1 relaxation time of liver parenchyma due to an increase of extracellular matrix and protein concentration. T1 mapping techniques also allow the estimation of extracellular volume fraction (ECV) from native and post-contrast T1. ECV values are calculated from the change in relaxation rate (R1 = 1/T1) of blood and parenchyma corrected for the hematocrit (Hct) [7]. Therefore, calculation of ECV requires Hct sampling. MRI-derived ECV using T1 mapping techniques is currently of increased interest as a new non-invasive tool for liver fibrosis assessment [7–12]. There are already studies, demonstrating a high diagnostic performance of ECV in liver fibrosis assessment in both, animal and human models [7, 9]. ECV correlates with histological markers of liver fibrosis and has a high diagnostic performance for liver fibrosis assessment with accuracies up to 85% depending on underlying liver disease and fibrosis stage [7, 9, 13–15]. Furthermore, the longitudinal reflexivity (R1 = 1/T1) of blood is known to be in a linear relationship with blood Hct. It is determined by the water fractions of plasma and the erythrocyte cytoplasm, which undergo fast water exchange [16–21]. Previous cardiac MRI studies showed that ECV quantification without blood sampling, assuming a linear relationship between blood Hct and longitudinal T1 relaxation times (1/T1blood), is feasible [22, 23]. But there are still no studies showing whether it is also applicable for calculation of hepatic ECV. A synthetic ECV calculation would be beneficial considering the fact that liver fibrosis assessment and staging using T1 mapping techniques could be performed non-invasively and time-efficient directly after the MRI examination.

The hypothesis of our study was that a linear relationship between blood Hct and longitudinal T1 relaxation times (1/T1blood) could be used for synthetic Hct estimation, which permits synthetic ECV calculation without Hct sampling. The aim of this study was (1) to create a synthetic Hct regression model and (2) to investigate whether synthetic Hct can be used for reliable and valid calculation of synthetic ECV compared to conventional ECV.

Materials and methods

This study was approved by the institutional review board. Written informed consent was obtained from all participants prior to MRI examination. From March 2019 to November 2020, consecutive patients with clinical indications for liver MRI examination were included in this study. Patients with and without chronic liver disease were included. Diagnosis of chronic liver disease was based on past medical history (including liver biopsy, clinical and laboratory examinations) and MRI (including MR-elastography). When necessary, the presence of significant fibrosis at MRI was assessed by MR-elastography as a reference standard using previous published cutoffs [3, 4]. Exclusion criteria were contraindications for contrast-enhanced MRI. Hematocrit samples were derived directly prior to MRI examination. According to the underlying liver disease, all patients were randomly split into the derivation and validation cohort. Clinical data and additional laboratory markers were recorded from the patient charts. Biochemical blood analyses were performed using standard tests and non-invasive scoring systems based on laboratory tests for assessment of liver fibrosis (aspartate aminotransferase-to-platelet ratio index (ARPI), fibrosis index based on the 4 factor (FIB-4), MELD score (Model of End Stage Liver Disease) and aspartate aminotransferase and alanine aminotransferase ratio (AST/ALT ratio (de-Ritis)) were calculated [24–26].

Magnetic resonance imaging

All participants underwent MRI examination on a clinical whole-body 1.5-T system (Ingenia, Philips Healthcare) equipped with 32-channel abdominal coil with digital interface for signal reception. In addition to morphological sequences, patients underwent hepatic T1 mapping with a heart rate independent 10-(2)-7-(2)-5-(2)-3-(2) modified Look-Locker inversion recovery (MOLLi) acquisition scheme with internal triggering [27]. Technical parameters were as follows: time of repetition/time of echo 1.92/0.84 ms, flip angle 20°, parallel imaging factor 2, acquired voxel size 1.98×2.45×10 mm, reconstructed voxel size 1.13×1.13×10 mm, scan duration/breath-hold 14.0 s. For the post-contrast T1 maps, the same technique was used after 10 min of contrast agent application in the same positions as pre-contrast examinations. T1 maps were acquired in end-expiration [28]. For contrast-enhanced T1 mapping, a gadolinium-based contrast agent (Gadobutrol, 1.0 mmol/ml solution with 0.1 mmol per kilogram of body weight, Gadovist, Bayer Healthcare Pharmaceuticals) was administered as a single bolus with an injection rate of 1.5 ml/s. Hepatic quantitative maps were acquired in a single transversal slice at the level of the bifurcation of portal vein. Relaxation maps were reconstructed directly at the scanner console. Liver MR-elastography was performed with a 2D gradient-recalled echo sequence to acquire liver elasticity maps with motion-encoding gradients. MR-elastography measurements were performed as previously described [8].
Image analysis

An experienced board-certified radiologist (J.A.L, 8 years of experience in abdominal MRI) performed image analyses, blinded to the clinical data. For the assessment of T1 relaxation times, the mean relaxation time of three representative regions of interest (ROI) (≥ 1 cm²), drawn centrally in the hepatic segments II, IVa and VII, were calculated (see also Fig. 1). Blood pool T1 values were derived from the abdominal aorta. In the derivation cohort as well as whole study cohort conventional ECV values were normalized for blood Hct and calculated with ROI-based on pre- and post-contrast T1 values according to the previously published equation [29]: ECV = (1 − hematocrit) × (1/T1 parenchyma post-contrast − 1/T1 parenchyma pre-contrast)/(1/T1 aortic post-contrast − 1/T1 aortic pre-contrast).

Proof-of-concept: synthetic hepatic ECV calculation

The longitudinal relaxivity of blood (R1 = 1/T1) demonstrate a linear relationship with blood Hct, and is determined by the relaxivity of the water fractions of plasma (R1p) and the erythrocyte cytoplasm (R1RBC) [17]: R1blood = R1p × (1 − Hct) + R1RBC × Hct. Hence, synthetic Hct was derived from the linear relationship between Hct and R1blood and used to calculate synthetic ECV. Synthetic ECV was normalized for synthetic Hct and calculated using the same equation as conventional ECV. Synthetic and conventional ECV were then compared.

Statistical analysis

Statistical analysis was performed using software (SPSS Statistics, version 25, IBM; Prism 8, GraphPad Software). Patient characteristics are presented as mean ± standard deviation or as absolute frequency, as appropriate. Student t test was used for comparison of continuous variables between two different groups. Dichotomous variables were compared using the χ² test (with the cell count > 5) and Fisher test (with a cell count ≤ 5). A locally derived synthetic ECV was created from the longitudinal relaxivity of blood (R1, or 1/T1). This model was created using linear regression, where R1 is the predictor variable and the measured Hct is the outcome. The bivariate Pearson correlation coefficient (r) was used for a correlation analysis between synthetic and blood Hct as well as synthetic and conventional ECV. Agreement between individual sets of blood and synthetic Hct as well as conventional and synthetic ECV was analyzed and represented graphically using the Bland–Altman method. The level of statistical significance was set to P < 0.05.
**Results**

**Cohort characteristics**

A total of 180 consecutive patients were included. In the whole study cohort, 87.8% (158/180) of patients had diffuse liver disease and 12.2% (22/180) of patients did not have diffuse liver disease based on past medical history, clinical and laboratory examinations as well as MR-elastography. The mean MR-elastography derived liver stiffness in the group of patients without chronic and/or fibrotic liver disease was 2.1 ± 0.5 kPa. This group of patients consisted of patients with indications for liver MRI examinations as follows: non-specific abdominal symptoms, e.g., non-specific abdominal pain (11/22, 50.0%) or liver lesions detection or/and characterization (11/22, 50.0%). Indications for all MRI examinations in patients with diffuse liver disease were follow-up and/or or malignancy exclusion by known chronic liver disease. Etiologies of liver diseases included: alcoholic liver disease (n=27, 15.0%); autoimmune liver diseases, including autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis (n=80, 44.4%); non-alcoholic fatty liver disease (n=12, 6.7%); viral hepatitis (n=13, 7.2%) and other rare etiologies such as portal sinusoidal disease, Budd–Chiari syndrome and Fontan-associated hepatopathy (n=5/180, 2.8%) as well as cryptogenic hepatopathy (n=21, 11.7%). All patients were randomly divided into the derivation (n=90) and validation (n=90) cohorts. The derivation cohort was used to establish the linear regression equation for calculation of synthetic Htc and ECV. The clinical characteristics of the derivation and validation cohorts are presented in Table 1.

**MRI results**

**Derivation cohort**

For the applied hepatic T1 MOLLI mapping sequence, the regression line between hematocrit and R1blood was linear with \( R^2 = 0.75, P < 0.001 \). The regression equation for Htc was: Synthetic HtcMOLLI = 98.04 × (1/T1blood) − 33.17, where Htc is hematocrit (1 to 100%) and R1blood = 1/T1blood in 10⁻³ s (see also Fig. 2). No significant differences in blood and synthetic Hct (38.5 ± 6.1% vs. 38.5 ± 5.3%, \( P > 0.05 \)) as well as between conventional and synthetic ECV (32.7 ± 8.5% vs. 32.6 ± 7.9%, \( P > 0.05 \)) were found using the above-mentioned equation. Moreover, we found significant correlations between synthetic and blood Htc (\( r = 0.87 \)) as well as synthetic and conventional ECV (\( r = 0.99 \)), in each case \( P < 0.001 \) (see also Fig. 3).

**Validation cohort**

Using above-named equation derived from derivation cohort in the validation cohort, we found no significant differences between blood and synthetic Htc values (39.6 ± 5.1% vs. 38.6 ± 4.8%, \( P > 0.05 \)) as well as conventional and synthetic ECV (30.0 ± 6.7% vs. 30.6 ± 6.9%, \( P > 0.05 \)). Moreover, synthetic and conventional ECV were highly correlated (\( r = 0.97, P < 0.001 \)). Synthetic and blood Hct also correlated well (\( r = 0.81, P < 0.001 \)). Bland–Altman analysis demonstrated minimal bias for both Hct (−0.97 ± 3.25%, 95% limits of agreement: −7.4% to 5.4%) as well as ECV (0.53 ± 1.67, 95% limits of agreement: −2.75% to −3.82%) (see also Figs. 4, 5 and 6). MRI characteristics of patients in the derivation and validation cohorts are presented in Table 2.

Moreover, we found also strong correlation between conventional and synthetic ECV in patients with chronic liver disease in the whole study cohort with a Pearson's correlation coefficient of 0.98 (\( P < 0.001 \)).

**Discussion**

The purpose of our study was to (1) create locally derived synthetic Hct values from the linear relationship between blood Hct and the longitudinal relaxivity (R1) of the blood and (2) investigate whether synthetic Hct can be used for reliable and valid calculation of synthetic hepatic ECV compared to conventional hepatic ECV. The main findings of our study are that: (1) synthetic Hct derived from linear regression modeling showed a strong correlation with blood Hct and, (2) synthetic ECV showed a strong correlation with conventional ECV and minimal bias according to the Bland–Altman analysis and, therefore, has a potential to be used as a reliable valid biomarker in routine clinical practice alternatively to conventional ECV.

Liver fibrogenesis in patients with chronic liver disease is a consequence of cellular damage and following regeneration processes, leading to increased production of connective tissue with extracellular matrix components. This process leads to the extension of extracellular space and an increased accumulation of extracellular contrast agents, which is reflected by prolonged native T1 relaxation times and increased ECV of the liver. Therefore, with a growing body of evidence, calculation of ECV is considered a new promising potential biomarker for non-invasive assessment of liver fibrosis [7–9]. Therefore, parametric MRI mapping including ECV requires routine clinical use of mapping beyond morphological sequences. However, calculation of ECV requires hematocrit sampling, which may limit the application and availability of these techniques in routine clinical practice. As a result, attempts have been made to...
eliminate the necessity for blood Htc through estimation of a synthetic Htc in order to calculate an ECV based on the observed linear relationship between Htc and blood R1 (1/T1blood). However, the clinical validity of this approach for abdominal applications has not been established yet. A few recent studies in cardiac MRI already demonstrated that synthetic ECV quantification without blood sampling might be a reliable valid tool compared with conventional ECV [22, 23, 30]. However, to our knowledge, there are still no studies showing whether this is also applicable for calculation of hepatic ECV.

In our study we implemented a simple to obtain synthetic ECV measurement using Hct derived from pre-contrast blood T1. The linear relationship between Hct and R1blood has been sufficiently investigated [17, 19–21, 31, 32], and, therefore, we used R1 for curve fitting. We found strong correlations between blood and synthetic Hct with Pearson’s correlation coefficient of 0.81 and 0.83 in the validation as

| Variable                              | Derivation cohort (n=90) | Validation cohort (n=90) | P value |
|---------------------------------------|--------------------------|--------------------------|---------|
| Age (years)                           | 47.7±16.7                | 48.6±15.4                | 0.71    |
| Body mass index (kg/m²)               | 25.6±4.8                 | 25.3±5.3                 | 0.71    |
| Sex                                   |                          |                          | 0.88    |
| Male                                  | 48                       | 47                       |         |
| Female                                | 42                       | 43                       |         |
| Blood hematocrit level (%)            | 38.5±6.1                 | 39.6±5.1                 | 0.21    |
| Underlying liver disease              |                          |                          |         |
| Primary sclerosing cholangitis (PSC) | 22 (24.4%)               | 21 (23.3%)               | 0.88    |
| Autoimmune hepatitis (AIH)           | 8 (8.9%)                 | 9 (15%)                  | 0.88    |
| AIH/PSC overlap syndrome              | 8 (8.9%)                 | 8 (8.9%)                 | 1.00    |
| Primary biliary cirrhosis             | 2 (22.2%)                | 2 (22.2%)                | 1.00    |
| Alcoholic liver disease               | 14 (15.5%)               | 13 (7.2%)                | 0.88    |
| Viral hepatitis                       | 6 (6.7%)                 | 7 (3.9%)                 | 0.88    |
| Non-alcoholic fatty liver disease (NASH) | 6 (6.7%)               | 6 (6.7%)                 | 1.00    |
| Portal sinusoid disease               | 1 (1.1%)                 | 1 (1.1%)                 | 1.00    |
| Unknown                               | 11 (15.0%)               | 10 (8.9%)                | 0.88    |
| Fontan-associated hepatopathy         | 1 (1.1%)                 | 1 (1.1%)                 | 1.00    |
| Budd–Chiari syndrome                  | 0 (0%)                   | 1 (1.1%)                 |         |
| No chronic liver disease              | 11 (12.2%)               | 11 (12.2%)               | 1.00    |
| Laboratory parameters                 |                          |                          |         |
| Bilirubin (mg/dl)                     | 1.33±1.9                 | 1.0±0.74                 | 0.16    |
| ALT (U/l)                             | 77.0±146.1               | 62.6±87.7                | 0.43    |
| AST (U/l)                             | 69.7±105.3               | 51.1±48.5                | 0.14    |
| GGT (U/l)                             | 182.7±230.5              | 121.9±150.6              | 0.04    |
| Platelets cells x 10⁹/l               | 222.1±109.7              | 228.1±111.9              | 0.72    |
| C-reactive protein level (mg/l)       | 11.6±21.3                | 5.2±7.7                  | 0.01    |
| AP (U/l)                              | 178.2±181.1              | 122.4±84.6               | 0.01    |
| Creatinine (mg/dl)                    | 0.86±0.29                | 0.90±0.41                | 0.45    |
| Albumin (g/l)                         | 39.0±10.4                | 41.2±8.4                 | 0.18    |
| International normalized ratio        | 1.16±0.36                | 1.09±0.16                | 0.11    |
| ASL/ALT (de-Ritis)                    | 1.27±0.9                 | 1.07±0.57                | 0.07    |
| FIB-4                                 | 2.9±3.5                  | 2.3±2.8                  | 0.22    |
| MELD                                  | 9.0±4.5                  | 8.43±3.6                 | 0.35    |
| APRI                                  | 1.01±1.57                | 0.76±0.98                | 0.20    |

Continuous data are means±standard deviations. Nominal data are absolute frequencies with percentages in parentheses.

MELD Score Model of End Stage Liver Disease, ALT alanine aminotransferase, AST aspartate aminotransferase, AP alkaline phosphatase, GGT gamma-glutamyltransferase, APRI aspartate aminotransferase-to-platelet ratio index, FIB-4 fibrosis-4 score, ASL/ALT (de-Ritis) De-Ritis ratio.
well as the whole study cohort, respectively ($P<0.001$ in each case). There were also strong correlations between conventional and synthetic ECV in the validation as well as the whole study cohort with $r=0.97$ and 0.99, respectively ($P<0.001$ in each case). As far as the results of this study can be compared with the results of previous cardiac studies, these findings support previous data, demonstrating higher correlations between synthetic and conventional ECV compared to synthetic and blood Hct [22, 23]. On the one hand it could be explained by a considerable error in Htc laboratory tests. On the other hand, ECV has other dependencies and additional terms, making it a more stable and robust parameter [33, 34]. Therefore, there could be more inaccuracy as a result of Hct measurements than that as a result of variations in T1 mapping approaches [35, 36]. However, regardless of excellent linear regression fit and in general strong correlations between blood and synthetic Htc as well as conventional and synthetic ECV values, the main disadvantage of synthetic ECV application is that it might lead to considerable errors in individual cases. According to Bland–Altman analysis these variations in

Fig. 2 Derivation cohort: Correlation $R_1_{\text{blood}}$ versus hematocrit using abdominal T1 MOLLI mapping sequence. The regression line between hematocrit and pre-contrast $R_1_{\text{blood}}$ was linear with $R^2=0.75$, $P<0.001$ with regression equation as given in the graph. Regression line is given with 95% confidence interval. MOLLI modified Look-Locker Inversion Recovery

Fig. 3 Derivation cohort: synthetic versus blood hematocrit (a, b) as well as synthetic versus conventional ECV (c, d). Scatter plots shows correlations between synthetic and blood Hct as well as synthetic and conventional ECV ($n=90$) (a, c). Bland–Altman plots of mean differences between blood and synthetic Htc as well as conventional and synthetic ECV. The mean value of measurements for both approaches is plotted on the x-axis and the difference between techniques is plotted on the y-axis. The solid black horizontal line plots the mean difference and the dotted black lines indicate the limits of agreement (differences from the mean of 1.96 SDs) for each parameter (b, d). Htc hematocrit, ECV extracellular volume fraction
individual measurement sets may reach up to 6% between blood and synthetic Hct and up to 4% between conventional and synthetic ECV (see also Figs. 4 and 5). Although the variations between conventional and synthetic ECV were less than 2%, higher variations may have clinical importance for liver fibrosis staging. Patients could be misclassified in a wrong fibrosis stage, which is especially vital for the detection of significant fibrosis. The presence of even greater variabilities was also demonstrated in previous cardiac studies, with more pronounced differences in Htc than in ECV values [22, 23]. The variability in laboratory Htc and calibration of conventional ECV to blood Hct may also lead to miscategorization. Hence, precise clinical evaluation based on medical history, laboratory examinations as well as MRI (including, e.g., MR-elastography) in individual patients are needed to minimize the possible discrepancies between synthetic and conventional values and therefore its influence on clinical decision-making (Table 3).

There are several limitations in our study. The main limitation was that the sample size was modest and all examinations were performed in a single center. Furthermore, the fact that T1 mapping techniques vary across the institutions can additionally limit the applicability of our study results. Furthermore, synthetic Hct requires local
calibration, unless MRI scanner, used T1 mapping parameters, and machine for Hct laboratory are the same. Moreover, as the accuracy of current T1 measurements method remains to be established, this study does not claim to report an accurate measure of T1, but that synthetic calculation of hepatic Hct derived from used T1 MOLLI sequence is a stable and reliable approach for routine clinical practice. Another significant limitation for clinical application of synthetic measurements is that equations for synthetic Hct calculation should be derived individually on each MRI scanner using the same acquisition scheme. Therefore, if synthetic ECV is to be used in routine clinical practice where blood Hct cannot be obtained, using a locally derived synthetic Hct regression model for the used T1 mapping sequence is preferred.

Fig. 6 Representative images of conventional and synthetic hepatic extracellular volume (ECV) maps from a 30-year-old male patient with no diffuse liver disease (a), from a 24-year-old female patient with autoimmune hepatitis and advanced fibrosis (fibrosis stage (F) 3, b) and a 49-year-old male patient with alcoholic liver disease and cirrhosis (F4, c) with corresponding MR elastograms. ECV extracellular volume fraction

Table 2 MRI characteristics of patients in the derivation and validation cohorts

| Variable                        | Derivation cohort (n = 90) | Validation cohort (n = 90) | P value |
|---------------------------------|---------------------------|---------------------------|---------|
| Hepatic native T1 relaxation time (ms) | 600.5 ± 108.3            | 571.5 ± 94.0              | 0.06    |
| Native T1 relaxation time of blood (ms) | 1376.6 ± 106.9           | 1372.3 ± 99.4             | 0.78    |
| Conventional extracellular volume fraction (%) | 32.7 ± 8.5              | 30.0 ± 6.7                | 0.02    |
| Synthetic extracellular volume fraction (%) | 32.6 ± 7.9              | 30.6 ± 6.9                | 0.06    |
| Synthetic hematocrit (%) | 38.5 ± 5.3               | 38.6 ± 4.8                | 0.83    |
| MR-elastography derived liver stiffness | 4.5 ± 1.6                | 4.2 ± 1.9                 | 0.46    |

Continuous data are means ± standard deviations
In conclusion, this is the first study investigating the applicability of synthetic hepatic Hct derived from a regression model for ECV calculation without Htc sampling. Our findings suggest that ECV calculated from synthetic Hct may be a useful, valid and reliable tool compared with conventional ECV. Further multi-centric prospective studies on a larger population are needed to validate these findings across the centers, using different T1 mapping sequences to enable the further clinical implementation of ECV by liver examinations. The use of synthetic ECV may potentially overcome an important barrier for clinical implementation of hepatic ECV measurements.

Author contribution J.A.L. and N.M. guarantors of integrity of entire study, contributed substantially to data acquisition, analysis, and interpretation; N.M. wrote the main manuscript text and prepared the figures and tables; all authors manuscript drafting or manuscript revision for important intellectual content; all authors approval of final version of submitted manuscript; J.A.L. and N.M. literature research; J.A.L. and N.M. manuscript editing.

Funding Open Access funding enabled and organized by Projekt DEAL. The authors did not receive support from any organization for the submitted work.

Data Availability The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Conflicts of interest The authors have no relevant financial or non-financial interests to disclose.

Ethical approval This study was performed in line with the principles of the Declaration of Helsinki. Institutional Review Board of University Hospital Bonn approval was obtained.

Consent to participate Written informed consent was obtained from all subjects (patients) in this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Moon AM, Singal AG, Tapper EB (2020) Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol 18:2650–2666. https://doi.org/10.1016/j.cgh.2019.07.060
2. Asrani SK, Devarthavi H, Eaton J et al. (2019) Burden of liver diseases in the world. Journal of Hepatology 70. https://doi.org/10.1016/j.jhep.2018.09.014
3. Singh S, Venkatesh SK, Wang Z, et al. (2015) Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 13:440–451.e6. https://doi.org/10.1016/j.cgh.2014.09.046
4. Hoodeshenas S, Yin M, Venkatesh SK (2018) Magnetic Resonance Elastography of Liver: Current Update. Top Magn Reson Imaging 27:319–333. https://doi.org/10.1097/RMR.0000000000000177
5. Guo Y, Parthasarathy S, Goyal P, et al. (2015) Magnetic resonance elastography and acoustic radiation force impulse for staging hepatic fibrosis: a meta-analysis. Abdom Imaging 40:818–834. https://doi.org/10.1007/s00261-014-0137-6
6. Wagner M, Corcuera-Solano I, Lo G, et al. (2017) Technical Failure of MR Elastography Examinations of the Liver: Experience from a Large Single-Center Study. Radiology 284:401–412. https://doi.org/10.1148/radiol.2016160865
7. Luetkens JA, Klein S, Traber F, et al. (2018) Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. Radiology 288:748–754. https://doi.org/10.1148/radiol.2018180051
8. Mesropyan N, Kupczyk P, Dold L, et al. (2020) Non-invasive assessment of liver fibrosis in autoimmune hepatitis: Diagnostic value of liver magnetic resonance parametric mapping including extracellular volume fraction. Abdom Radiol (NY) . https://doi.org/10.1007/s00261-020-02822-x
9. Luetkens JA, Klein S, Traebber F, et al. (2018) Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. Gut 67:593–594. https://doi.org/10.1136/gutjnl-2017-314561
10. Hoffman DH, Ayoola A, Nickel D, et al. (2020) MR elastography, T1 and T2 relaxometry of liver: role in noninvasive assessment...
11. MRI of the liver: Evaluation of extracellular volume fraction and other quantitative parameters in comparison to MR elastography for the assessment of hepatopathy. Magnetic Resonance Imaging 77:7–13. https://doi.org/10.1016/j.mri.2020.12.005

13. Kupczyk PA, Mesropyan N, Isaak A, et al. (2021) Quantitative MRI of the liver: Evaluation of extracellular volume fraction and other quantitative parameters in comparison to MR elastography for the assessment of hepatopathy. Magnetic Resonance Imaging 77:7–13. https://doi.org/10.1016/j.mri.2020.12.005

15. Yoon JH, Lee JM, Kim JH, et al. (2021) Hepatic fibrosis grading with extracellular volume fraction from iodine mapping in spectral liver CT. Eur J Radiol 137: https://doi.org/10.1016/j.ejrad.2021.109664

16. Spees WM, Yablonskiy DA, Oswood MC, et al. (2001) Water proton MR properties of human blood at 1.5 Tesla: magnetic susceptibility, T1, T2, T*2, and non-Lorentzian signal behavior. Magn Reson Med 45:533–542. https://doi.org/10.1002/mrm.1072

17. Li W, Gracq K, Huang H, A et al. (2016) Quantitative theory for the longitudinal relaxation time of blood. Magn Reson Med 76:270–281. https://doi.org/10.1002/mrm.25875

18. Shimada K, Nagasaka T, Shidahara M, et al. (2012) In vivo measurement of longitudinal relaxation time of human blood by inversion-recovery fast gradient-echo MR imaging at 3T. Magn Reson Med Sci 11:265–271. https://doi.org/10.2463/mrms.11.265

19. Lu H, Clingman C, Golay X, et al. (2004) Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla. Magn Reson Med 52:679–682. https://doi.org/10.1002/mrm.20178

20. Martin MA, Tatton WG, Lemaire C et al. (1990) Determination of extracellular/intracellular fluid ratios from magnetic resonance images: accuracy, feasibility, and implementation. Magn Reson Med 15. https://doi.org/10.1002/mrm.191015050107

21. Pechnik SK, Ferreira VM, Lewandowski AJ et al. (2013) Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson 15:13. https://doi.org/10.1186/1532-429x-15-13

22. Treibel TA, Fontana M, Maestrini V et al. (2016) Automatic Measurement of the Myocardial Interstitium: Synthetic Extracellular Volume Quantification Without Hematocrit Sampling. JACC. Cardiovascular imaging 9. https://doi.org/10.1016/j.jcmg.2015.11.008

23. Raucci FJ, Parra DA, Christensen JT, et al. (2017) Synthetic hematocrit derived from the longitudinal relaxation of blood can lead to clinically significant errors in measurement of extracellular volume fraction in pediatric and young adult patients. J Cardiovasc Magn Reson 19:58. https://doi.org/10.1186/s12968-017-0377-z

24. Li J, Gordon SC, Rupp LB et al. (2014) The validity of serum markers for fibrosis staging in chronic hepatitis B and C. Journal of viral hepatitis 21. https://doi.org/10.1111/jvh.12224

25. Sterling RK, Lissen E, Clunneke N, et al. (2006) Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43:1317–1325. https://doi.org/10.1002/hep.21178

26. Imperiale TF, Born LJ (2001) Clinical utility of the AST/ALT ratio in chronic hepatitis C. Am J Gastroenterol 96:919–920. https://doi.org/10.1111/j.1572-0241.2001.03647.x

27. Messroghli DR, Radjenovic A, Kozerke S, et al. (2004) Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 52:141–146. https://doi.org/10.1002/mrm.20110

28. Vu K-N, Haldipur AG, Roh AT-H et al. (2019) Comparison of End-Expiration Versus End-Inspiration Breath-Holds With Respect to Respiratory Motion Artifacts on T1-Weighted Abdominal MRI. AJR Am J Roentgenol:1–6. https://doi.org/10.2214/ajr.18.20239

29. Schelbert EB, Messroghli DR (2016) State of the Art: Clinical Applications of Cardiac T1 Mapping. Radiology 278:658–676. https://doi.org/10.1148/radiol.2016141802

30. Robison S, Karur GR, Wald RM, et al. (2018) Noninvasive hematocrit assessment for cardiovascular magnetic resonance extracellular volume quantification using a point-of-care device and synthetic derivation. J Cardiovasc Magn Reson 20:19. https://doi.org/10.1186/s12898-018-0443-1

31. Fullerton GD, Potter JL, Dorribluth NC (1982) NMR relaxation of protons in tissues and other macromolecular water solutions. Magnetic Resonance Imaging 1:209–226. https://doi.org/10.1016/0730-725X(82)90172-2

32. Braunwiesiger PG, Schiffer L, Furmaniski P (1986) The measurement of extracellular water volumes in tissues by Gadolinium modification of 1H-NMR spin lattice (T1) relaxation. Magnetic Resonance Imaging 4:285–291. https://doi.org/10.1016/0730-725X(86)91038-6

33. Ugander M, Oki AJ, Hsu L-Y, et al. (2012) Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J 33:1268–1278. https://doi.org/10.1093/eurheartj/ehr481

34. Wong TC, Pehler K, Meier CG, et al. (2012) Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126:1206–1216. https://doi.org/10.1161/CIRCULATIONAHA.111.089409

35. Roujol S, Weingärtner S, Foppa M, et al. (2014) Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology 272:683–689. https://doi.org/10.1148/radiol.14140296

36. Kellman P, Arai AE, Xue H (2013) T1 and extracellular volume mapping of the heart. Magn Reson Med 52:141–146. https://doi.org/10.1002/mrm.20110

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.